CRVS vs. QURE
CRVS (Corvus Pharmaceuticals, Inc.) and QURE (uniQure N.V.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, CRVS returned 0.06%/yr vs 11.46%/yr for QURE. At a 0.29 correlation, their price movements are largely independent.
Performance
CRVS vs. QURE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRVS achieves a 54.94% return, which is significantly higher than QURE's 15.21% return. Over the past 10 years, CRVS has underperformed QURE with an annualized return of 0.06%, while QURE has yielded a comparatively higher 11.46% annualized return.
CRVS
- 1D
- 2.84%
- 1M
- -24.68%
- YTD
- 54.94%
- 6M
- 42.53%
- 1Y
- 181.37%
- 3Y*
- 53.32%
- 5Y*
- 33.63%
- 10Y*
- 0.06%
QURE
- 1D
- 2.80%
- 1M
- -5.49%
- YTD
- 15.21%
- 6M
- 41.31%
- 1Y
- 72.42%
- 3Y*
- 10.96%
- 5Y*
- -5.23%
- 10Y*
- 11.46%
CRVS vs. QURE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 54.94% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 48.23% | -64.58% | -27.55% |
QURE uniQure N.V. | 15.21% | 35.50% | 160.86% | -70.14% | 9.31% | -42.60% | -49.58% | 148.65% | 47.12% | 249.82% |
Correlation
The correlation between CRVS and QURE is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Mar 23, 2016 | 0.29 |
Fundamentals
CRVS:
$1.07B
QURE:
$1.73B
CRVS:
-$0.53
QURE:
-$3.58
CRVS:
4.46
QURE:
11.58
CRVS:
$0.00
QURE:
$18.09M
CRVS:
-$26.00K
QURE:
$13.42M
CRVS:
-$47.43M
QURE:
-$164.53M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRVS vs. QURE — Risk / Return Rank
CRVS
QURE
CRVS vs. QURE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and uniQure N.V. (QURE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRVS | QURE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.74 | ||
| Sortino ratioReturn per unit of downside risk | +1.26 | ||
| Omega ratioGain probability vs. loss probability | 1.48 | 1.45 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 3.23 | 0.83 | +2.40 |
| Martin ratioReturn relative to average drawdown | 7.03 | 1.35 | +5.68 |
Loading charts...
Drawdowns
CRVS vs. QURE - Drawdown Comparison
The maximum CRVS drawdown since its inception was -96.97%, roughly equal to the maximum QURE drawdown of -95.40%. Use the drawdown chart below to compare losses from any high point for CRVS and QURE.
Loading charts...
Drawdown Indicators
| CRVS | QURE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.97% | -95.40% | -1.57% |
Max Drawdown (1Y)Largest decline over 1 year | -56.43% | -87.21% | +30.78% |
Max Drawdown (3Y)Largest decline over 3 years | -70.50% | -87.21% | +16.71% |
Max Drawdown (5Y)Largest decline over 5 years | -92.40% | -90.11% | -2.29% |
Max Drawdown (10Y)Largest decline over 10 years | -96.97% | -95.40% | -1.57% |
Current DrawdownCurrent decline from peak | -53.25% | -66.46% | +13.21% |
Average DrawdownAverage peak-to-trough decline | -69.28% | -56.61% | -12.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.91% | 53.75% | -27.84% |
Volatility
CRVS vs. QURE - Volatility Comparison
Corvus Pharmaceuticals, Inc. (CRVS) and uniQure N.V. (QURE) have volatilities of 23.12% and 24.13%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRVS | QURE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.12% | 24.13% | -1.01% |
Volatility (6M)Calculated over the trailing 6-month period | 111.88% | 92.07% | +19.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 180.64% | 273.03% | -92.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 131.02% | 154.02% | -23.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.13% | 119.76% | -8.63% |
Dividends
CRVS vs. QURE - Dividend Comparison
Neither CRVS nor QURE has paid dividends to shareholders.
Financials
CRVS vs. QURE - Financials Comparison
This section allows you to compare key financial metrics between Corvus Pharmaceuticals, Inc. and uniQure N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRVS and QURE have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QURE has higher volatility (24.13%) compared to CRVS (23.12%). In terms of maximum drawdown, CRVS dropped -96.97% vs QURE's -95.40%.
CRVS currently has the higher Sharpe Ratio (1.01 vs 0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRVS and QURE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer